AstraZeneca PLC Mulls $10 Billion Bid for Medivation
AstraZeneca (LON:AZN) is considering tabling a last-minute bid for $10 billion (£7.7 billion) US oncology specialist Medivation, The Sunday Times has reported. The US group, which sells a blockbuster treatment for prostate cancer, is reportedly courting bidders.
AstraZeneca’s share price has headed south this morning, having lost 1.06 percent to 4,525.50p as of 08:47 BST. The shares are underperforming the broader London market, with the benchmark FTSE 100 index having climbed marginally into positive territory and currently standing 0.20 percent
AstraZeneca’s share price has headed south this morning, having lost 1.06 percent to 4,525.50p as of 08:47 BST. The shares are underperforming the broader London market, with the benchmark FTSE 100 index having climbed marginally into positive territory and currently standing 0.20 percent